Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic Dermatitis
September 17, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Trea
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
September 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 07, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
July 16, 2024 16:01 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 06, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 07, 2024 16:01 ET
|
Aclaris Therapeutics, Inc.
Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update
April 30, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
February 27, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for...
Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review
January 16, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
- Douglas Manion, M.D. to step down as Chief Executive Officer, President and Member of Board of Directors - - Dr. Neal Walker, Current Chairman and Co-founder, Appointed as Interim Chief Executive...
Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis
January 10, 2024 07:00 ET
|
Aclaris Therapeutics, Inc.
- ATI-1777 2% BID Achieved a Statistically Significant Result in the Primary Efficacy Endpoint at Week 4 - - Minimal Systemic Exposure Supports “Soft” Topical JAK Inhibitor Approach - - ATI-1777...